NVO News

RO HELPS PATIENTS SAVE UP TO $1,200 PER YEAR ON WEGOVY® THROUGH COLLABORATION WITH NOVO NORDISK

Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year

Heart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney Health

Novo Nordisk A/S - share repurchase programme

Remedy Meds GLP-1 Weight Loss 2026: Pricing, the FDA Compounding Shakeup, and What to Know Before You Commit to a Monthly Plan

FDA approves Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General Obesity

Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes